Equity Profile

STVN

Stevanato Group S.p.A.

Health CareLife Sciences Tools & Services$5.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Stevanato Group S.p.A. is a key player in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of profitability, and this quarter's estimate reflects market expectations for growth.

$0.15

Revenue

Revenue figures will help gauge overall business performance and demand for Stevanato's products.

$298M

Wall Street expectations, options signals, track record, and call prep available with Pro.

STVN Q2-2026 Earnings Preview

Context

Company Snapshot

Stevanato Group S.p.A. is a key player in the health care sector, specializing in life sciences tools and services. The company focuses on providing innovative solutions for the pharmaceutical and biotechnology industries, which are critical for drug delivery and packaging.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+4.93%

Avg Stock Reaction

+4.40%

Last Quarter Recap

In Q1-2026, Stevanato reported an EPS of $0.13, surpassing expectations by nearly 6%. However, the stock fell by over 5% the following day, indicating market caution.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Stevanato's upcoming earnings, with expectations for a slight increase in EPS and revenue. The market is closely watching how the company performs against these estimates.

Bull Case

If Stevanato beats EPS and revenue expectations, it could signal strong demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses its targets, it may raise concerns about its growth trajectory and market position, potentially leading to a significant stock decline.

Key Metrics to Watch

EPS

$0.15

Earnings per share is a crucial indicator of profitability, and this quarter's estimate reflects market expectations for growth.

Revenue

$298M

Revenue figures will help gauge overall business performance and demand for Stevanato's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed $0.15, indicating stronger profitability than expected?

A beat on EPS could signal robust demand and operational efficiency, which the market will likely reward.

How does revenue compare to the $298M consensus, and what are management's insights on future demand?

Revenue performance will provide insight into the company's growth trajectory and market position, critical for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches and increased demand in the pharmaceutical sector.

Supporting Evidence

Stevanato has a history of beating EPS estimates, which could indicate stronger operational performance than expected.

The options market is pricing in a significant move, suggesting that investors anticipate volatility that may not align with consensus expectations.

Key Risk

If revenue comes in below $293M, it could undermine confidence in the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Stevanato can maintain its growth momentum amid competitive pressures and economic conditions.

Bull Confirmed If

An EPS of $0.15 or higher, with revenue exceeding $298M, would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.14 or revenue falling short of $293M would raise concerns about growth and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±34.08%

Historical Avg

±8.7%

Pricing rich

The options market is pricing in a substantial move, suggesting that investors expect significant volatility following the earnings report.

Options are pricing ±34.1% while STVN has averaged ±8.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.1%

Calls (300)P/C Ratio: 0.11Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Stevanato beats expectations, history suggests a potential stock increase of around 1.1% on the following day.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 13.55% based on historical patterns when the company has underperformed.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on demand trends in the pharmaceutical sector.
3Insights into cost management and operational efficiencies.
4Guidance on future earnings and revenue expectations.
5Any discussion on competitive pressures and market share.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Stevanato Group S.p.A. is a key player in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of profitability, and this quarter's estimate reflects market expectations for growth.

$0.15

Revenue

Revenue figures will help gauge overall business performance and demand for Stevanato's products.

$298M

Wall Street expectations, options signals, track record, and call prep available with Pro.

STVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+4.93%

Avg Stock Reaction

+4.40%

Last Quarter Recap

In Q1-2026, Stevanato reported an EPS of $0.13, surpassing expectations by nearly 6%. However, the stock fell by over 5% the following day, indicating market caution.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Stevanato beats EPS and revenue expectations, it could signal strong demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses its targets, it may raise concerns about its growth trajectory and market position, potentially leading to a significant stock decline.

Key Metrics to Watch

EPS

$0.15

Earnings per share is a crucial indicator of profitability, and this quarter's estimate reflects market expectations for growth.

Revenue

$298M

Revenue figures will help gauge overall business performance and demand for Stevanato's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed $0.15, indicating stronger profitability than expected?

A beat on EPS could signal robust demand and operational efficiency, which the market will likely reward.

How does revenue compare to the $298M consensus, and what are management's insights on future demand?

Revenue performance will provide insight into the company's growth trajectory and market position, critical for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches and increased demand in the pharmaceutical sector.

Supporting Evidence

Stevanato has a history of beating EPS estimates, which could indicate stronger operational performance than expected.

The options market is pricing in a significant move, suggesting that investors anticipate volatility that may not align with consensus expectations.

Key Risk

If revenue comes in below $293M, it could undermine confidence in the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Stevanato can maintain its growth momentum amid competitive pressures and economic conditions.

Bull Confirmed If

An EPS of $0.15 or higher, with revenue exceeding $298M, would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.14 or revenue falling short of $293M would raise concerns about growth and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±34.08%

Historical Avg

±8.7%

Pricing rich

The options market is pricing in a substantial move, suggesting that investors expect significant volatility following the earnings report.

Options are pricing ±34.1% while STVN has averaged ±8.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

36.1%

Calls (300)P/C Ratio: 0.11Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Stevanato beats expectations, history suggests a potential stock increase of around 1.1% on the following day.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 13.55% based on historical patterns when the company has underperformed.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on demand trends in the pharmaceutical sector.
3Insights into cost management and operational efficiencies.
4Guidance on future earnings and revenue expectations.
5Any discussion on competitive pressures and market share.